Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224793 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03224793 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 32 participants.
The verdict
NCT03224793, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
To assess the safety and tolerability of single, subcutaneous (SC) doses of BIIB059 in healthy Japanese subjects.
Interventions
- DRUG Placebo
- DRUG BIIB059
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2018-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03224793
The ClinicalTrials.gov registry entry for NCT03224793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03224793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03224793 about?
NCT03224793 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.". To assess the safety and tolerability of single, subcutaneous (SC) doses of BIIB059 in healthy Japanese subjects.
What is the current status of trial NCT03224793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-10-04. Estimated completion is 2018-06-12.
What interventions are being tested in trial NCT03224793?
The interventions under investigation include: Placebo (DRUG), BIIB059 (DRUG).
Who is sponsoring clinical trial NCT03224793?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.